10-QPeriod: Q1 FY2025

INTUITIVE SURGICAL INC Quarterly Report for Q1 Ended Mar 31, 2025

Filed April 23, 2025For Securities:ISRG

Summary

Intuitive Surgical Inc. (ISRG) reported strong financial results for the first quarter of 2025, demonstrating robust top-line growth and continued expansion in its core robotic surgery business. Total revenue increased by a significant 19% year-over-year to $2.25 billion, driven by strong performance across all revenue segments, particularly in instruments and accessories, systems, and services. The company saw a substantial increase in da Vinci procedure volume, up 17%, alongside a notable 58% surge in Ion endoluminal procedures, indicating growing adoption of its minimally invasive solutions. Key financial metrics highlight the company's operational efficiency and continued investment in innovation. Gross profit margin remained healthy at 64.7%, with operating income growing 23%. The company also reported a healthy cash position, ending the quarter with $9.10 billion in cash, cash equivalents, and investments, providing ample liquidity for future growth initiatives, ongoing R&D, and potential strategic acquisitions. The increase in systems revenue and strong da Vinci 5 system placements signal positive market reception for newer generation products.

Financial Highlights

45 data points
Beta

Revenue

$2.25B

64.7% Gross Margin

Net Income

$698.40M

31.0% Net Margin

EPS (Diluted)

$1.92

Total Assets

$19.22B

Cash & Equivalents

$2.57B

Free Cash Flow

$581.60M

Financial Statements
Beta
Revenue$2.25B
Cost of Revenue$795.70M
Gross Profit$1.46B
R&D Expenses$316.20M
SG&A Expenses$563.40M
Operating Expenses$879.60M
Operating Income$578.10M
Net Income$698.40M
EPS (Basic)$1.95
EPS (Diluted)$1.92
Shares Outstanding (Basic)357.50M
Shares Outstanding (Diluted)364.60M

Key Highlights

  • 1Total revenue grew 19% to $2.25 billion, driven by strong performance across all segments.
  • 2Da Vinci procedures increased by 17%, indicating continued adoption of robotic surgery.
  • 3Ion endoluminal procedures saw substantial growth of 58%, highlighting expansion beyond traditional surgery.
  • 4Instruments and accessories revenue grew 18%, reflecting increased procedure volume.
  • 5Systems revenue increased by 25%, boosted by higher da Vinci system placements, including 147 da Vinci 5 systems.
  • 6Operating income rose 23%, demonstrating effective cost management and operational leverage.
  • 7The company maintained a strong liquidity position with $9.10 billion in cash, cash equivalents, and investments.

Frequently Asked Questions

Revenue growth was primarily driven by a 17% increase in da Vinci procedures and a 58% increase in Ion procedures. This led to an 18% increase in instruments and accessories revenue, a 25% increase in systems revenue, and a 16% increase in service revenue. The strong performance of the da Vinci 5 system placements also contributed significantly to the systems revenue growth.

The company notes that while the impact of tariffs on its first quarter 2025 results was immaterial, it anticipates a significant increase in its cost of revenues in the second half of 2025 due to recently announced and implemented global tariffs. It is actively monitoring supply chain risks, inflationary pressures, and elevated interest rates, and is engaged in activities to mitigate their impact on operations. Specific concerns include tariffs on imports from China impacting da Vinci Xi surgical system costs and competitiveness in that region.

Intuitive Surgical is continuing to advance its product pipeline. The company reported FDA clearance for its SP SureForm 45 stapler and curved-tip stapler in March 2025 for use with the da Vinci SP surgical system. The phased launch of the next-generation da Vinci 5 system is progressing, with 147 units placed in Q1 2025. The Ion endoluminal system also continues to see strong procedural growth and installed base expansion.

The company faces ongoing product liability litigation related to the da Vinci surgical system. It is also involved in patent and commercial litigation, including antitrust claims related to the service and repair of its instruments. While the company is defending itself, it acknowledges that the ultimate outcome of these matters could have a material adverse effect on its business, financial condition, or future results of operations. The company cannot estimate a range of loss for certain legal matters.